Actub, Rachel B.
HRN: 22-95-03 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/24/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
04/24/2023
04/30/2023
IV
500mg
Q8hrs
Amoebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes